Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00171457 · ClinicalTrials.gov registry record · Phase 3
The Effects of Tegaserod on Mechanical Sensitivity of the Esophagus and Stomach in Patients With Heartburn and Dyspepsia.
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 24
- Enrollment target
NCT00171457 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 24 participants.
The verdict
NCT00171457, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 24 participants
- Enrollment target
Study Summary
Investigate the role of tegaserod in modulating gastric sensitivity to mechanical distention of the stomach
Interventions
- DRUG Tegaserod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2005-04 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00171457
The ClinicalTrials.gov registry entry for NCT00171457 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tegaserod is the first listed.
NCT00171457 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00171457 about?
NCT00171457 is a clinical study titled "The Effects of Tegaserod on Mechanical Sensitivity of the Esophagus and Stomach in Patients With Heartburn and Dyspepsia.". Investigate the role of tegaserod in modulating gastric sensitivity to mechanical distention of the stomach
What is the current status of trial NCT00171457?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 24 participants. The study started on 2005-04. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00171457?
The interventions under investigation include: Tegaserod (DRUG).
Who is sponsoring clinical trial NCT00171457?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.